Singular Genomics Systems, Inc. to Report First Quarter 2022 Financial Results on May 10, 2022
Singular Genomics Systems will disclose its Q1 2022 financial results on May 10, 2022, after market close. A conference call for management's discussion of results is scheduled for 1:30 p.m. PT / 4:30 p.m. ET. The company focuses on next-generation sequencing and multiomics technologies, aiming to enhance research and clinical applications. Singular's products, including the G4 and the upcoming PX, support its mission to advance genomics in science and medicine.
- Development of two products, G4 targeting NGS market and PX for versatile multiomics solutions.
- None.
LA JOLLA, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc., a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the first quarter 2022 after the market close on Tuesday, May 10, 2022. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at investor.singulargenomics.com, in the Presentations & Events section.
About Singular Genomics Systems, Inc.
Singular Genomics is a life science technology company that is leveraging novel NGS and multiomics technologies to build products that empower researchers and clinicians. Our mission is to accelerate genomics for the advancement of science and medicine. Our Singular Sequencing Engine is the foundational platform technology that forms the basis of our products as well as our core product tenets: power, speed, flexibility, and accuracy. We are currently developing two products that are purpose-built to target applications in which these core product tenets matter most. Our first product, the G4, targets the NGS market. Our second product in development, the PX, combines single-cell analysis, spatial analysis, genomics and proteomics in one integrated instrument to offer a versatile multiomics solution.
Investor Contact
Matt Clawson
949-370-8500
ir@singulargenomics.com
Media Contact
Dan Budwick, 1AB
973-271-6085
dan@1abmedia.com
FAQ
When will Singular Genomics report its Q1 2022 financial results?
What time is the Singular Genomics conference call?
How can I listen to the Singular Genomics conference call?
What technologies does Singular Genomics specialize in?
